Compare Bristol-Myers Squibb Co (BMY) vs H2O America (HTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs H2O America — how do they compare? Bristol-Myers Squibb Co trades at $58.65 (market cap $116.30B), while H2O America trades at $63.14 (market cap $2.63B). The key difference: Bristol-Myers Squibb Co is far larger — about 44.2× H2O America's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | HTO | |
|---|---|---|
Market Cap | $116.30B | $2.63B |
Sector | Health | Technology |
52-Week High | $62.37 | $62.94 |
52-Week Low | $42.60 | $44.44 |
Enterprise Value | $152.24B | $4.35B |
Dividend Yield | 4.42% | 2.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
HTO trades at $62.47, up 1.63% with strong technical momentum and bullish analyst sentiment. The stock shows solid fundamentals with 12.87% net margins and consistent earnings beats in recent quarters. Recent news highlights institutional buying and upcoming Q2 2026 earnings on July 27, 2026, while the company maintains a $0.44 dividend payout.
Outlook remains positive with 80% analyst buy ratings and a $62 consensus target. Key risks include execution of the $2.7B capex plan and regulatory exposure as a utility. The stock offers stable growth potential through rate base expansion and strategic acquisitions like Quadvest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →
